[go: up one dir, main page]

WO2017046873A1 - Source de lumière laser - Google Patents

Source de lumière laser Download PDF

Info

Publication number
WO2017046873A1
WO2017046873A1 PCT/JP2015/076162 JP2015076162W WO2017046873A1 WO 2017046873 A1 WO2017046873 A1 WO 2017046873A1 JP 2015076162 W JP2015076162 W JP 2015076162W WO 2017046873 A1 WO2017046873 A1 WO 2017046873A1
Authority
WO
WIPO (PCT)
Prior art keywords
laser light
light source
intensity
wavelength
filter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2015/076162
Other languages
English (en)
Japanese (ja)
Inventor
史生 正田
柳澤　隆行
渡辺　憲一
菅野　哲生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Electric Engineering Co Ltd
Mitsubishi Electric Corp
Original Assignee
Mitsubishi Electric Engineering Co Ltd
Mitsubishi Electric Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Electric Engineering Co Ltd, Mitsubishi Electric Corp filed Critical Mitsubishi Electric Engineering Co Ltd
Priority to PCT/JP2015/076162 priority Critical patent/WO2017046873A1/fr
Publication of WO2017046873A1 publication Critical patent/WO2017046873A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S3/00—Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range

Definitions

  • the present invention relates to a laser light source, which is a medical light source used for treatment or diagnosis using light of a specific wavelength component such as photodynamic therapy (PDT) or photodynamic diagnosis (PDD). It is.
  • a laser light source which is a medical light source used for treatment or diagnosis using light of a specific wavelength component such as photodynamic therapy (PDT) or photodynamic diagnosis (PDD). It is.
  • the laser light source is used as a medical light source for various treatments or diagnoses such as PDT or PDD.
  • PDT is a method for selectively treating tumor tissue by irradiating a photosensitive substance accumulated in a main tissue with laser light.
  • the photosensitizer for example, resaphyrin or 5-aminolevulinic acid (5-ALA) is used, and a laser beam corresponding to the excitation wavelength of these substances is irradiated to treat a tumor or the like using a photochemical reaction. I do.
  • PDD also injects a phosphor such as indocyanine green (ICG) or fluorescein into a blood vessel, and irradiates the affected area with near-infrared light corresponding to excitation light, thereby causing the phosphor to emit light. It is used as a landmark.
  • ICG indocyanine green
  • fluorescein a phosphor such as fluorescein
  • Patent Document 1 describes a mechanism that detects the intensity of laser light and detects an output abnormality based on the detection result.
  • the present invention has been made to solve the above-described problems, and in a laser light source that is a medical light source, even if the wavelength of the laser light varies with respect to the conventional configuration, it is given to the irradiated object.
  • An object of the present invention is to provide a laser light source capable of suppressing fluctuations in influence.
  • a laser light source includes a light source that outputs laser light, a light separator that separates a part of the laser light output by the light source, and a transmittance corresponding to the wavelength characteristic of sensitivity of the irradiated object to the laser light.
  • a filter that has wavelength characteristics and transmits the laser beam separated by the optical separator, a photodetector that detects the intensity of the laser beam that has passed through the filter, and the output intensity of the light source based on the detection result by the photodetector And a control unit for controlling.
  • the present invention since it is configured as described above, in the laser light source that is a medical light source, even when the wavelength of the laser light varies compared to the conventional configuration, the variation in the influence on the irradiated object is suppressed. be able to.
  • FIG. 1 is a schematic diagram showing a configuration example of a laser light source according to Embodiment 1 of the present invention.
  • the laser light source is a medical light source used for treatment or diagnosis using light of a specific wavelength component.
  • the laser light source includes a light source 1, a light separator 2, a filter 3, a photodetector 4, and a control unit 5.
  • the filter 3 and the photodetector 4 constitute a monitor unit.
  • the light source 1 outputs laser light.
  • the light source 1 is disposed at a position for irradiating an irradiation object such as a human body, and outputs a laser beam having a wavelength corresponding to the excitation wavelength of a drug administered to the irradiation object.
  • the light source 1 may be a light source that can output laser light having a wavelength corresponding to the excitation wavelength of the drug, and may be of any type, such as a semiconductor laser, a solid-state laser, or a liquid laser.
  • the laser output from the light source 1 may be continuous or pulsed.
  • the light separator 2 is disposed between the light source 1 and the irradiated object, and separates (reflects) a part of the laser light output from the light source 1.
  • a glass material is used as the light separator 2.
  • the light separator 2 is arranged at a fixed angle with respect to the optical axis so as to divide the laser light into a transmitted light component and a reflected light component with respect to the wavelength of the laser light.
  • the laser light separated by the light separator 2 is output as monitor light to the monitor unit, and most of the other laser light that has passed through the light separator 2 is emitted to the irradiated object (human body in the example of FIG. 1). Used for its original purpose.
  • the filter 3 transmits the laser light (monitor light) separated by the light separator 2.
  • This filter 3 has a wavelength characteristic of transmittance corresponding to the wavelength characteristic of the sensitivity of the irradiated object to the laser light.
  • the wavelength characteristic of the sensitivity is a wavelength characteristic of sensitivity at a target site (a site of a lesion, a site where diagnosis or treatment is performed) of an irradiation object.
  • the wavelength characteristic of the transmittance of the filter 3 will be described later.
  • the light detector 4 is disposed on the same optical axis as the filter 3 and detects the intensity of the laser light transmitted through the filter 3.
  • the photodetector 4 includes a photodiode (PD) and a current-voltage conversion circuit.
  • the PD receives laser light that has passed through the filter 3 and converts it into a current value.
  • the current-voltage conversion circuit converts the current value into a voltage value. Note that PD can detect only the intensity of the laser beam because of its characteristics, and cannot detect the wavelength of the laser beam.
  • a detection result (a signal indicating a voltage value) by the photodetector 4 is output to an electrically connected control unit 5.
  • the controller 5 is electrically connected to the photodetector 4 and controls the output intensity of the light source 1 based on the detection result (signal indicating the voltage value) by the photodetector 4. Specifically, the control unit 5 determines whether the intensity of the laser light detected by the photodetector 4 is within a predetermined intensity or a predetermined range based on the predetermined intensity. And when it determines with a laser beam being the said intensity
  • the current value applied to the light source 1 is increased or decreased so as to be within the above-mentioned intensity or the above-mentioned range.
  • the operations of the monitor unit and the control unit 5 are performed in real time.
  • the hardware configuration of the control unit 5 includes, for example, a processor 51 and a memory 52 as shown in FIG.
  • the control unit 5 shown in FIG. 1 is realized by a processor 51 that executes a program stored in a memory 52.
  • the plurality of processors 51 and the plurality of memories 52 may execute the above functions in cooperation.
  • the irradiated object is a human body.
  • a photosensitive substance such as resorphyrin or 5-ALA is administered to the human body in advance.
  • the photosensitive material When the photosensitive material is irradiated with laser light, the photosensitive material absorbs the energy and enters an excited singlet state in which the energy is increased. This state is not maintained for a long time, and a part of the photosensitive substance emits excitation energy as fluorescence and returns to the original ground state. On the other hand, the rest of the photosensitive substance transitions to a triplet state due to energy intersystem crossing. Then, some photosensitive substances in the triplet state emit phosphorescence and return to the ground state. On the other hand, the energy of the remaining photosensitive substance in the triplet state is further transferred to the triplet oxygen present in the tissue. The triplet oxygen that has undergone this energy transfer is excited to become singlet oxygen (active oxygen) with high activity. Various treatments can be performed by degenerating or necrosing surrounding cells with this single oxygen.
  • the photochemical action of Rezaphyrin is based on the above principle, but is not limited to that principle. That is, it is clear that the same effect can be obtained if a substance that absorbs light and denatures or necroses the surrounding cells can be generated and lesions such as cancer cells can be damaged.
  • FIG. 3 is a graph showing the wavelength characteristics of the absorption amount of laser light of resaphyrin (solid line) and hemoglobin (broken line). As shown in FIG. 3, resorphyrin has a higher absorption rate around 660 nm than hemoglobin. Therefore, a light source 1 that can output laser light having a wavelength near 660 nm is used.
  • the influence on the human body indicates the amount of active oxygen generated by irradiating the target site with laser light, and has wavelength dependency. This characteristic varies depending on the lesion, and is determined by factors that inhibit the tissue penetration of laser light (mainly hemoglobin, fat, and melanin in PDT). Therefore, in the present invention, the filter 3 having the wavelength characteristic of the transmittance corresponding to the wavelength characteristic of the sensitivity of the human body to the laser beam in the treatment is used.
  • FIG. 4 shows the relationship between the wavelength characteristic of the sensitivity of the human body (solid line) and the filter characteristic of the transmittance of the filter 3 (broken line).
  • the wavelength characteristic of the transmittance of the filter 3 is determined based on the wavelength characteristic of the sensitivity of the human body. That is, the wavelength characteristic of the transmittance of the filter 3 is determined so that the transmittance is small for a wavelength with low human sensitivity, and the transmittance is large for a wavelength with high human sensitivity. ing.
  • the filter 3 can be produced by forming a dielectric thin film or a metal thin film on the surface of an optical base material such as a parallel plate optical glass. For example, a high refractive index layer and a low refractive index layer made of a dielectric thin film are alternately laminated. At this time, the filter 3 having a predetermined transmittance with respect to the wavelength can be obtained by appropriately setting the material, film thickness, number of stacked layers, and the like of each high refractive index layer and each low refractive index layer.
  • the light source 1 outputs laser light (step ST501).
  • the light separator 2 separates a part of the laser light output from the light source 1 (step ST502).
  • the filter 3 transmits the laser beam separated by the light separator 2 (step ST503).
  • the filter 3 has a wavelength characteristic of transmittance corresponding to the wavelength characteristic of the sensitivity of the human body. Therefore, the transmittance increases at a wavelength where the sensitivity of the human body is large, and the transmittance decreases at a wavelength where the sensitivity of the human body is small.
  • the photodetector 4 detects the intensity of the laser beam that has passed through the filter 3 (step ST504).
  • control unit 5 controls the output intensity of the light source 1 based on the detection result by the photodetector 4 (step ST505).
  • the control unit 5 first determines whether the intensity of the laser light detected by the photodetector 4 is within a predetermined intensity or a predetermined range based on the predetermined intensity. And when it determines with a laser beam being the said intensity
  • the control unit 5 adjusts the intensity of the laser beam so that the influence on the human body is constant.
  • FIGS. 6 and 7 the case where the wavelength of the laser light changes from ⁇ 1 to ⁇ 2 is shown separately when there is no filter 3 (conventional configuration) and when it is present (configuration of the present invention). Note that ⁇ 2 has a low sensitivity to the human body at the same intensity of the laser beam as compared to ⁇ 1, and has a small influence on the human body.
  • the filter 3 when the filter 3 is not provided, the output intensity of the laser light remains constant even if the wavelength of the laser light varies from ⁇ 1 to ⁇ 2.
  • the sensitivity of the human body is smaller at ⁇ 2 than at ⁇ 1, as shown in FIG. 6B, the influence on the human body (the generation amount of active oxygen) is also reduced.
  • the wavelength variation occurs in the laser beam, the influence on the human body varies, and stable treatment cannot be performed.
  • the transmittance of the filter 3 decreases when the wavelength of the laser light varies from ⁇ 1 to ⁇ 2, and therefore FIG.
  • the controller 5 increases the current applied to the light source 1, and the output intensity of the light source 1 increases.
  • the sensitivity of the human body is reduced by changing from ⁇ 1 to ⁇ 2. Therefore, as shown in FIG. 7C, the influence on the human body (the amount of generated active oxygen) remains constant.
  • the present invention is not limited to this.
  • laser light having a wavelength near 400 nm is used as the excitation wavelength of rezaphyrin
  • the same effect as described above can be obtained by using the filter 3 having a desired transmittance near 400 nm even when laser light near 400 nm is used.
  • the same effect as described above can be obtained by configuring the laser light source according to the excitation wavelength.
  • the optical separator 2 that separates a part of the laser beam output from the light source 1 and the transmittance corresponding to the wavelength characteristic of the sensitivity of the irradiated object to the laser beam. Based on a detection result of the filter 3 having a wavelength characteristic, a filter 3 that transmits the laser light separated by the light separator 2, a light detector 4 that detects the intensity of the laser light transmitted through the filter 3, and the light detector 4.
  • the control unit 5 that controls the output intensity of the light source 1 is provided, the laser light source that is a medical light source is applied to the irradiated object even when the wavelength of the laser light fluctuates with respect to the conventional configuration. The fluctuation of influence can be suppressed.
  • the intensity of the laser light depends on the wavelength dependence of the sensitivity of the irradiated object to the laser light in treatment. Can be adjusted automatically, and stable treatment can be realized.
  • the operation of the monitor unit and the control unit 5 is continuously performed in real time during the laser operation and the output intensity of the light source 1 is controlled, the influence on the irradiated object can always be made constant and stable. Treatment or diagnosis can be realized.
  • the intensity of the laser beam transmitted through the filter 3 is greatly attenuated.
  • the intensity detected by the photodetector 4 is also extremely small. Therefore, a lower limit value (specified value) of the laser light detected by the light detector 4 is determined in advance, and an alarm device (for example, a warning) that issues an alarm when the intensity detected by the light detector 4 falls below the specified value.
  • an alarm device for example, a warning
  • a monitor for display or a speaker for generating an error sound may be provided.
  • a warning can be notified to the user of the laser light source when the intensity of the laser beam is attenuated due to the wavelength shift so that treatment or diagnosis is difficult. Further, it is possible to prevent laser light from being output at a wavelength greatly deviating from the sensitivity of the irradiated object, and to prevent unnecessary power consumption for laser driving.
  • the sensitivity of the irradiated object has different characteristics depending on the target site (the depth of the lesion, the site of treatment or diagnosis). Therefore, the optimal therapeutic effect or diagnostic effect can be obtained by using the filter 3 having a transmittance corresponding to the target site.
  • the present invention is not limited to this.
  • the present invention can be similarly applied to a PDD in which fluorescence observation is performed using a fluorescent agent such as ICG or fluorescein as a drug.
  • a fluorescent agent such as ICG or fluorescein as a drug.
  • fluorescence observation a fluorescent agent is administered to an irradiated object, and a laser beam corresponding to the excitation wavelength of the fluorescent agent is incident to cause the fluorescent agent to fluoresce, and treatment or diagnosis is performed using this as a mark. is there.
  • the present invention can be modified with any component of the embodiment or omitted with any component of the embodiment.
  • the laser light source according to the present invention can suppress the fluctuation of the influence on the irradiated object even when the wavelength of the laser light fluctuates, and is suitable for use as a laser light source that is a medical light source.
  • 1 light source 2 light separator, 3 filter, 4 light detector, 5 control unit, 51 processor, 52 memory.

Landscapes

  • Health & Medical Sciences (AREA)
  • Electromagnetism (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Plasma & Fusion (AREA)
  • Optics & Photonics (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

La présente invention est pourvue d'une source de lumière (1) qui émet une lumière laser, d'un séparateur de lumière (2) qui sépare une partie de la lumière laser émise par la source de lumière (1), d'un filtre (3) qui transmet la lumière laser séparée par le séparateur (2) et possède des caractéristiques de longueur d'onde de transmittance correspondant à des caractéristiques de longueur d'onde de la sensibilité à la lumière laser d'un objet soumis au rayonnement de la lumière laser, d'un photodétecteur (4) qui détecte l'intensité de la lumière laser transmise à travers le filtre (3) et d'une unité de commande (5) qui commande l'intensité d'émission de la source de lumière (1) sur la base des résultats de détection provenant du photodétecteur (4).
PCT/JP2015/076162 2015-09-15 2015-09-15 Source de lumière laser Ceased WO2017046873A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2015/076162 WO2017046873A1 (fr) 2015-09-15 2015-09-15 Source de lumière laser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2015/076162 WO2017046873A1 (fr) 2015-09-15 2015-09-15 Source de lumière laser

Publications (1)

Publication Number Publication Date
WO2017046873A1 true WO2017046873A1 (fr) 2017-03-23

Family

ID=58288306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/076162 Ceased WO2017046873A1 (fr) 2015-09-15 2015-09-15 Source de lumière laser

Country Status (1)

Country Link
WO (1) WO2017046873A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360385B2 (fr) * 1980-01-23 1988-11-24
JPH05160497A (ja) * 1991-12-09 1993-06-25 Fuji Photo Film Co Ltd 半導体レーザーの光出力安定化装置
JPH07100218A (ja) * 1993-10-06 1995-04-18 Matsushita Electric Ind Co Ltd 光化学治療診断装置
JP2003284738A (ja) * 2002-03-28 2003-10-07 Nidek Co Ltd レーザ治療装置
JP2005083872A (ja) * 2003-09-08 2005-03-31 Fuji Photo Film Co Ltd 表示装置
WO2007149601A2 (fr) * 2006-02-01 2007-12-27 The General Hospital Corporation Appareil destiné à commander au moins l'une d'au moins deux sections d'au moins une fibre
WO2010100898A1 (fr) * 2009-03-04 2010-09-10 三菱電機株式会社 Appareil de source de lumière laser et appareil d'affichage d'image

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360385B2 (fr) * 1980-01-23 1988-11-24
JPH05160497A (ja) * 1991-12-09 1993-06-25 Fuji Photo Film Co Ltd 半導体レーザーの光出力安定化装置
JPH07100218A (ja) * 1993-10-06 1995-04-18 Matsushita Electric Ind Co Ltd 光化学治療診断装置
JP2003284738A (ja) * 2002-03-28 2003-10-07 Nidek Co Ltd レーザ治療装置
JP2005083872A (ja) * 2003-09-08 2005-03-31 Fuji Photo Film Co Ltd 表示装置
WO2007149601A2 (fr) * 2006-02-01 2007-12-27 The General Hospital Corporation Appareil destiné à commander au moins l'une d'au moins deux sections d'au moins une fibre
WO2010100898A1 (fr) * 2009-03-04 2010-09-10 三菱電機株式会社 Appareil de source de lumière laser et appareil d'affichage d'image

Similar Documents

Publication Publication Date Title
US20130289672A1 (en) Laser therapy apparatus, laser therapy system, and determination method
WO2014185372A1 (fr) Dispositif et méthode de surveillance du niveau de progression d'une thérapie
RU2623299C2 (ru) Устройство для лечения кожи на основе энергии
JP2011218149A (ja) Ｐｄｔ用医療装置及び治療光制御方法
JP6122142B2 (ja) 角膜組織を監視するための装置、接合ユニット、吸引リング、および方法
JP6184086B2 (ja) 光治療装置
US20160287894A1 (en) Medical instrument and light-ray treatment device
AU2014340370B2 (en) Surgical laser treatment temperature monitoring
WO2011114653A1 (fr) Dispositif d'évaluation et procédé d'évaluation
JP6074115B2 (ja) 多光子ベースの皮膚処理のための皮膚処理装置
JP4190325B2 (ja) 固体レーザ装置及び固体レーザ装置によるレーザ照射方法
WO2015076262A1 (fr) Outil médical et dispositif photothérapeutique
JP2015097664A5 (fr)
KR101435436B1 (ko) 광 치료장치, 이의 동작 방법
WO2017046873A1 (fr) Source de lumière laser
JPH07100218A (ja) 光化学治療診断装置
CN110314034B (zh) 一种可实现个性治疗的角膜交联装置
US9819138B2 (en) Object information acquiring apparatus, laser apparatus, and medical apparatus
US20200129073A1 (en) Treatment system
CN115811998A (zh) 用于分布诊断用的辐射的系统和方法
US20250073493A1 (en) Photodynamic therapy and photoacoustic measurement coexistence system and method
JP2006271828A (ja) 医療用治療装置およびその装置の使用方法
JP2023062528A (ja) 光線力学療法治療支援装置
JP2006325987A (ja) レーザ光照射装置
Kianian A Multimodal Microvascular Imaging System for the Rodent Dorsal Skinfold Window Chamber: Development, Validation and Application

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15904062

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15904062

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP